Table 4.
Antibacterial agents | Non-nosocomial infections(n = 39) | Nosocomial infections(n = 19) | P value (χ2 test) |
ESBL test | 5 (12.8) | 7 (36.8) | 0.034 |
Ampicillin/sulbactam | 11 (28.2) | 12 (63.1) | 0.011 |
Piperacillin/tazobactam | 3 (7.7) | 5 (26.3) | 0.054 |
Ceftriaxone | 9 (23.1) | 11 (57.9) | 0.009 |
Cefepime | 8 (20.1) | 7 (36.8) | 0.183 |
Cefoperazone/sulbactam | 8 (20.1) | 9 (47.4) | 0.035 |
Ceftazidime | 10 (25.6) | 7 (36.8) | 0.098 |
Amikacin | 2 (5.1) | 1 (5.3) | 0.983 |
Gentamicin | 5 (12.8) | 7 (36.8) | 0.034 |
Ciprofloxacin | 10 (25.6) | 6 (31.6) | 0.635 |
Aztreonam | 8 (20.1) | 5 (26.3) | 0.619 |
Imipenem | 4 (10.3) | 3 (15.8) | 0.544 |
Meropenem | 2 (5.10) | 2 (10.5) | 0.446 |
ESBL test: Extended-spectrum β-lactamase test. P < 0.05 was considered statistically significant.